R42

"Our mission is straightforward but ambitious: to decarbonise the world’s most complex real estate in a way that is intelligent, automated and scalable. We don’t just tell you what to do, we do it for you. This funding allows us to double down on the growth and product investment needed to compete at scale."

"It is truly a pivotal time at Healx. By December 2024, we will advance HLX-1502 into a Phase 2 clinical trial in patients with NF1 both for plexiform neurofibroma, a genetic condition with limited treatment options and for cutaneous neurofibroma, for which there are no FDA approved options. We are also generating important preclinical data for multiple additional compounds identified using our novel generative AI drug discovery engine. Those compounds target rare diseases with significant unmet needs, including additional nerve-related tumor disorders, autosomal dominant polycystic kidney disease and neurodevelopmental disorders such as Angelman syndrome."

"X-ray scanners are such a common technology that we don’t often think of them as an area for innovation. But the reality is that the addressable market is huge – far beyond the obvious medical applications, with X-ray equipment critical in a range of sectors from construction to manufacturing. Silveray’s technology could play a key role in bringing the world’s oldest imaging technology into the 21st century."

"With the rise of remote working, financial institutions are struggling to deal with the sheer level of virtual communications they must analyse for regulatory purposes,"